Or­phan drug spe­cial­ist Hori­zon looks to dou­ble down on its gout ex­per­tise with ac­quired rights to Ar­row­head­'s RNAi ...

4 years ago
Deals

Covid-19 roundup: Af­ter win­ning an EUA, GSK and Vir are back with full da­ta on their mon­o­clon­al an­ti­body; New Zealand ...

4 years ago
Coronavirus

Ac­tivist in­vestor El­liott in talks with oth­er Glax­o­SmithK­line in­vestors about re­plac­ing Em­ma Walm­s­ley, spin­ning off ...

4 years ago
People
Pharma

No­var­tis bur­nish­es Zol­gens­ma da­ta in presymp­to­matic pa­tients as Roche's Evrys­di con­tin­ues eat­ing away at the SMA pie

4 years ago
R&D

Tar­sus nabs key da­ta in hunt to re­pur­pose dog drug as cure for eye par­a­site

4 years ago
R&D

HHS backs down in le­gal fight over drug dis­count pro­gram with As­traZeneca, Eli Lil­ly, No­vo and Sanofi

4 years ago
Pharma

Aduhelm OK 'bit­ter­sweet' for ALS ad­vo­cates; Con­trast­ing Covid-19 vac­cine read­outs; GSK joins TIG­IT bat­tle; and more

4 years ago
Weekly

FDA's con­tro­ver­sial Aduhelm de­ci­sion leaves ALS pa­tients feel­ing spurned

4 years ago
Pharma
In Focus

Jim Green­wood opens new pol­i­cy shop, with an eye on drug price con­trols; Mod­er­na, CRISPR, Mus­tang re­ceive tax breaks ...

4 years ago
News Briefing

Mod­er­na dips in­to J&J's tal­ent pool for Tal Zak­s' re­place­ment; Jim Mullen choos­es next chief sci­en­tist at Ed­i­tas ...

4 years ago
Peer Review

Who are the lu­mi­nar­ies dri­ving the biggest ad­vances in bio­phar­ma R&D? End­points News is ask­ing for your nom­i­na­tions ...

4 years ago
R&D

Spring reg­u­la­to­ry agen­da: What’s com­ing soon-ish from the FDA

4 years ago
FDA+

Hutchmed files for $600M+ IPO in Hong Kong as lead on­col­o­gy drug su­r­u­fa­tinib awaits FDA's good graces

4 years ago
Financing
China

Covid-19 roundup: Both As­traZeneca and EC claim a win in le­gal case over vac­cine de­lay; South Ko­rea to mix-and-match ...

4 years ago
Coronavirus

As drug­mak­ers spend $6B an­nu­al­ly on DTC ads, sen­a­tors re­vive bill to in­clude list prices in ads

4 years ago
Pharma

Biotech founder placed on leave as $400M Alzheimer's start­up idea comes un­der scruti­ny

4 years ago
People
R&D

An­oth­er four IPOs com­plete busy week as biotech raise con­tin­ues to match 2020's record pace

4 years ago
Financing

Af­ter roller-coast­er week, CRL forces a reck­on­ing on Or­p­hazyme in­vestors — in­flat­ed shares plum­met

4 years ago
FDA+

Sen. Manchin to Biden: Don't nom­i­nate Wood­cock for FDA com­mis­sion­er

4 years ago
FDA+

Bris­tol My­ers breaks the bank on Ei­sai's fo­late re­cep­tor ADC drug, lay­ing out more than $3B+ for rights

4 years ago
Deals

As spot­light trains on bio­phar­ma di­ver­si­ty, most com­pa­nies kept their C-suites ex­act­ly the same in 2020 — re­port

4 years ago
Pharma

In an ef­fort to safe­ly de­liv­er mR­NA, Stan­ford Uni­ver­si­ty teams up with Ger­man biotech Evonik

4 years ago
Deals
Manufacturing

'No rea­son to slow down any­thing here': Cure­Vac plans to march on with Covid-19 vac­cine af­ter piv­otal fail­ure

4 years ago
Coronavirus

Biden in­vests $3B in­to an­tivi­ral de­vel­op­ment for Covid-19

4 years ago
Coronavirus
First page Previous page 687688689690691692693 Next page Last page
A service from the Financial Times